Stoke Therapeutics Appoints G. Clare Kahn, Ph.D. to Board of Directors

On April 3, 2026, Stoke Therapeutics, Inc. expanded its Board of Directors to ten members and appointed G. Clare Kahn, Ph.D., as a Class I director, effective immediately. Dr. Kahn brings over 30 years of industry experience, having previously held leadership roles at X-VAX Technology Inc., Pfizer, and GlaxoSmithKline. She will serve on the Nominating and Corporate Governance Committee and chair the Research and Development Committee. Her term expires at the 2026 Annual Meeting of Stockholders. In connection with her appointment, Dr. Kahn will receive an annual cash retainer of $45,000 and was granted an initial stock option to purchase 30,782 shares of common stock, valued at approximately $724,000. These options will vest in twelve equal quarterly installments. The appointment comes as Stoke advances its Phase 3 study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen is an antisense oligonucleotide being developed in collaboration with Biogen and has received Breakthrough Therapy and Orphan Drug designations.